For the year ending 2025-12-31, VSTM had $116,172K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue-Product | 30,914 |
| Cost of sales - product | 4,600 |
| Cost of sales - intangible amortization | 698 |
| Research and development expenses | 112,065 |
| Commercial expenses | 34,316 |
| Medical affairs expenses | 11,046 |
| General and administrative expenses | 28,512 |
| Stock-based compensation expense | 9,405 |
| Depreciation expense | 32 |
| Interest income | 4,068 |
| Interest expense | 1,138 |
| Loss on debt extinguishment | -1,826 |
| Change in fair value of warrant liability | 27,492 |
| Change in fair value of notes | 12,751 |
| Other segment items | 572 |
| Net loss | -209,471 |
| Depreciation | 30 |
| Amortization of acquired intangible assets | 698 |
| Non-cash operating lease cost | -81 |
| Stock-based compensation expense | 9,404 |
| Amortization of deferred financing costs, debt discounts and premiums and discounts on available-for-sale marketable securities | 29 |
| Change in fair value of warrant liability | 27,492 |
| Non-cash change in fair value of notes | 6,560 |
| Loss on debt extinguishment | -1,826 |
| Accounts receivable, net | 8,813 |
| Inventory | 1,833 |
| Prepaid expenses, other current assets and other assets | 2,605 |
| Accounts payable | 8,422 |
| Accrued expenses and other liabilities | 30,833 |
| Net cash used in operating activities | -137,509 |
| Purchases of intangible assets | 9,624 |
| Net cash (used in) provided by investing activities | -9,624 |
| Proceeds from the issuance of common stock and pre-funded warrants, net | 196,976 |
| Proceeds from exercise of warrants | 33,792 |
| Proceeds from long-term debt | 75,000 |
| Repayment of long-term debt | 42,579 |
| Proceeds from insurance premium financing | 1,180 |
| Payments on insurance premium financing | 1,180 |
| Proceeds from the exercise of stock options and employee stock purchase program | 116 |
| Net cash provided by financing activities | 263,305 |
| Increase in cash, cash equivalents and restricted cash | 116,172 |
| Cash, cash equivalents and restricted cash at beginning of period | 89,059 |
| Cash, cash equivalents and restricted cash at end of period | 205,231 |
Verastem, Inc. (VSTM)
Verastem, Inc. (VSTM)